Insights
Search Insights
Upcoming Events
Watch On-Demand
Upcoming
Events
Get Anytime Access to Continuing Legal Education and Business Programming
Our new LearningLab: On-Demand Hub offers a growing library of continuing legal education (CLE) and business-focused legal insights you can now access anytime, anywhere.
October 1, 2026
Events
AI in Healthcare: From Innovation to Liability
Foley partner Aaron Tantleff is speaking in the upcoming Data Privacy for Health Summitt on the panel “AI in Healthcare: From Innovation to Liability.” From training data to regulatory scrutiny, this panel will explore how AI is transforming life sciences, and where responsibility lies when things go wrong.
October 9, 2026
Upcoming
Events
22nd Annual IP Conference
Foley & Lardner LLP is back in Boston for our 22nd Annual IP Conference! Join us on Friday, October 9, 2026, for a full day of insightful discussions led by industry voices from across the corporate and intellectual property landscape. This premier event will explore emerging trends, best practices in IP management, and key legal considerations, providing a valuable opportunity to:
Latest Blog Posts
October 7, 2026
Foley Career Perspectives
Different Strengths, One Team: An Interview With Texas Attorneys of the Year Chris Converse and Chris Babcock
The firm’s collaborative culture was on full display when partners Chris Converse and Chris Babcock worked together on a “rare kind of legal achievement” that required both strategic vision and deep technical analysis.
October 7, 2026
Foley Viewpoints
What Your Software Company Is Worth Now
Rob Bartlett of Jefferies joined the panel I moderated last month on whether companies should buy, sell, or wait. This week I read his team’s monthly software valuation update, with data through September 30. I read a lot of bank decks. This one I read twice.
October 7, 2026
Foley Viewpoints
Beyond Animal Testing: FDA's 2026 Framework for Fit-for-Purpose NAMs
In September 2026, FDA took another significant step toward integrating new approach methodologies, or NAMs, into drug development by issuing a Direct Final Rule on Nonclinical Testing Terminology (the “September 2026 direct final rule”).[
Latest Podcast Episodes
September 28, 2026
The Path & The Practice
Episode 147: Roland Potts, Partner
This episode features a conversation with Roland Potts. Roland is a partner in Foley’s Miami Office, Chair of the firm’s International Arbitration Team, and a member of the Commercial Litigation Practice Group.
September 23, 2026
Energized with Foley
From General Counsel to Growth Officer: A Lawyer's Path to Leading Energy's Next Chapter
In this episode of Energized by Foley, Deanna Reitman speaks with David Dardis, Senior Executive Vice President and Chief External Affairs and Growth Officer at Constellation Energy.
September 18, 2026
The Path & The Practice
Episode 146: Lawrence Kraus, Partner
In this conversation, Larry reflects on growing up in the Bronx, attending Brandeis University for undergrad and attending Harvard Law School. Larry reflects on his journey to Foley—including working for a number of years before attending law school—and his path to becoming a litigator.
Latest Viewpoints
October 7, 2026
Foley Viewpoints
The Growth Docket Vol. I, No. 4 – New Leaders, New Prices, Higher Rates
Joe Baratta leaves Blackstone at year-end, and Blackstone will not replace him. Hernan Cristerna, JPMorgan's longtime M&A chief, retires the same week. The generation that built modern private equity is handing over the keys. Growth equity is doing the same, with less press. Here is the week.
October 7, 2026
Foley Career Perspectives
Different Strengths, One Team: An Interview With Texas Attorneys of the Year Chris Converse and Chris Babcock
The firm’s collaborative culture was on full display when partners Chris Converse and Chris Babcock worked together on a “rare kind of legal achievement” that required both strategic vision and deep technical analysis.
October 7, 2026
Foley Viewpoints
What Your Software Company Is Worth Now
Rob Bartlett of Jefferies joined the panel I moderated last month on whether companies should buy, sell, or wait. This week I read his team’s monthly software valuation update, with data through September 30. I read a lot of bank decks. This one I read twice.